CorMedix CEO awarded 77,156 performance shares

CorMedix Inc. reported an equity award to its Chief Executive Officer and director Joseph Todisco.

Rhea-AI Filing Summary

CorMedix Inc. reported an equity award to its Chief Executive Officer and director Joseph Todisco. On February 4, 2026, he acquired 77,156 shares of common stock at $0.00 per share, following the achievement of performance stock units for the first of three performance periods granted on January 2, 2025.

After this transaction, Todisco beneficially owned 774,749 shares of CorMedix common stock, held directly. The performance stock units remain subject to time-based vesting conditions that must be satisfied by the reporting person before full vesting.

Insider Trade Summary

Grant/Award: 77,156 shares

Grant/Award 1 txn

Insider Todisco Joseph

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	77,156	$0.00	$0.00

Holdings After Transaction: Common Stock — 774,749 shares (Direct)

Footnotes (1)

1. F1. Represents the achievement of performance stock units ("PSUs") upon the determination of the Compensation Committee of the Issuer that the performance conditions specific to the first of three performance periods were met with respect to the PSUs granted to the Reporting Person on January 2, 2025. The PSUs are subject to vesting upon satisfaction of time-based vesting conditions by the Reporting Person.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CorMedix (CRMD) report for its CEO?

CorMedix reported that CEO and director Joseph Todisco acquired 77,156 shares of common stock on February 4, 2026 at $0.00 per share. The shares resulted from performance stock units achieved for the first of three performance periods granted January 2, 2025.

How many CorMedix (CRMD) shares does CEO Joseph Todisco hold after this Form 4?

Following the reported transaction, CEO Joseph Todisco beneficially owned 774,749 shares of CorMedix common stock directly. This total includes the 77,156 shares acquired upon achievement of performance stock units tied to the first performance period of a three-period PSU grant.

What triggered the 77,156-share award to the CorMedix (CRMD) CEO?

The 77,156-share award resulted from the achievement of performance stock units after the Compensation Committee determined performance conditions for the first of three performance periods were met. These PSUs were granted to the reporting person on January 2, 2025 under CorMedix’s performance framework.

Are the CorMedix (CRMD) CEO’s performance stock units fully vested?

The performance stock units are not fully vested; they remain subject to time-based vesting conditions. The units convert into shares upon both achievement of performance goals and satisfaction of ongoing time-based service requirements by the reporting person, as described in the Form 4 footnote.

What was the price per share for the CorMedix (CRMD) CEO’s acquired stock?

The 77,156 common shares reported in the Form 4 were acquired at a price of $0.00 per share. This reflects an award tied to performance stock units rather than an open-market purchase, as clarified in the transaction table and accompanying footnote.

What roles does Joseph Todisco hold at CorMedix (CRMD)?

Joseph Todisco is both a director and the Chief Executive Officer of CorMedix Inc., as indicated in the filing. The Form 4 identifies him as an officer with the title Chief Executive Officer and as a member of the company’s board of directors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/06/2026 - 09:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Todisco Joseph

(Last) (First) (Middle)

C/O CORMEDIX INC.,

389 INTERPACE PKWY, SUITE 450

(Street)

PARSIPPANY NJ 07054

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CorMedix Inc. [ CRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/04/2026		A		77,156	A	$0.00(1)	774,749	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the achievement of performance stock units ("PSUs") upon the determination of the Compensation Committee of the Issuer that the performance conditions specific to the first of three performance periods were met with respect to the PSUs granted to the Reporting Person on January 2, 2025. The PSUs are subject to vesting upon satisfaction of time-based vesting conditions by the Reporting Person.

	/s/ Beth Zelnick Kaufman, attorney-in-fact	02/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.